contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Isn’t this Control Resonant precisely a leap into a new game concept, a melee-based action RPG? It has skill trees and everything. It should, at least in theory, appeal to a larger player base.

Limited companies are supposed to make money, and this one hasn’t succeeded, so the share price drop is completely justified. There’s not much faith that it will in the future either… but that’s usually the best time to buy… a little more for the portfolio. I still consider this a potential success and a quality game developer, but isn’t that scene just not appealing enough to players? Should they also try making a slightly different type of game concept?

What a crappy show, and we didn’t see Resonantia, so we’ll have to see where we hear more about it.

After the previous CEO’s last few years, it’s good if the CEO focuses on doing rather than talking. From the CEO’s perspective, they should thoroughly familiarize themselves with the company and its culture, fulfill investor obligations (general meeting, annual report, Q1 report) even before Resonant, while the overwhelmingly most important task now is to achieve a successful global launch for Resonant. Until he gives reason for criticism with his actions - I’d say let him cook. After Resonant, there will be time for interviews, either from the limelight or the circus, depending on the outcome.  I wish I could refuse this indirect church tax for 2026. It seems I have no choice but to turn the other cheek.

The stock is indeed YTD -25%, even though an important major release is coming very soon… The new CEO, Jean-Charles Gaudechon, is at least keeping a “low profile,” and it’s hard to find any news about him related to Remedy, or much else for that matter.

As mentioned, the stock has dropped quite a bit. At the same time, Remedy’s most important game is just around the corner, which made me think it might be interesting to predict the stock price at the end of the year. I think we will see a lot of movement in both directions. Remedy’s stock price at the end of 2026:    under 10 euros 10-15 euros 15-25 euros 25-30 euros 30-40 euros 40-50 euros over 50 euros      0 äänestäjää     Let’s gauge the forum members’ expectations and we can come back to this later to see how many were on the right track

Remedy’s stock has fallen to about 11.5 euros. This is the level it was at before the release of Control in late summer 2019!  The decline feeds the decline. I’ve been thinking for a while about how the unpopularity of small-cap companies affects stock price declines through funds. For example, Evli’s small-cap fund reduced its weighting in Remedy.  According to Morningstar, its own performance looks like this, and it seems money is flowing out rapidly:  It would be interesting to study this for many small-cap companies. If funds give up like private investors, then “no one” is going to catch the shares.  The Church Pension Fund has also heavily dumped Remedy.

Remedy Entertainment

We reiterate our Accumulate recommendation for Remedy and raise our target price to EUR 50.0 (previously EUR 38.0) after the H2 report again strengthened our confidence in the company's long...

<p>We reiterate our Accumulate recommendation for Remedy and raise our target price to EUR 50.0 (previously EUR 38.0) after the H2 report again strengthened our confidence in the company's long-term value creation potential. Thanks to a multi-project model that has been built with controlled risks and is well-managed, Remedy’s preconditions for developing successful games are good. In addition, favorable market trends help the company grow into a clearly larger game house than currently over this decade. Due to a growth story that progresses strongly we still play the long game with the share, even though the valuation looks tight in the short term.</p> 

	2020	21e	22e
Revenue	41.1	45.9	48.8
growth-%	29.8 %	11.7 %	6.3 %
EBIT (adj.)	13.2	15.5	14.8
EBIT-% (adj.)	32.2 %	33.8 %	30.3 %
EPS (adj.)	0.86	1.02	0.97
Dividend	0.15	0.20	0.25
Dividend %	0.4 %	1.7 %	2.2 %
P/E (adj.)	45.5	11.3	11.8
EV/EBITDA	31.5	6.8	6.3

Remedy: We keep our eye on the long game

Login required

Key Estimate Figures14.02.2021

Forum discussions